Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Mar 1;173(3):224-233.
doi: 10.1001/jamapediatrics.2018.4826.

Epidemiology of Invasive Early-Onset and Late-Onset Group B Streptococcal Disease in the United States, 2006 to 2015: Multistate Laboratory and Population-Based Surveillance

Srinivas Acharya Nanduri  1 , Susan Petit  2 , Chad Smelser  3 , Mirasol Apostol  4 , Nisha B Alden  5 , Lee H Harrison  6 , Ruth Lynfield  7 , Paula S Vagnone  7 , Kari Burzlaff  8 , Nancy L Spina  8 , Elizabeth M Dufort  8 , William Schaffner  9 , Ann R Thomas  10 , Monica M Farley  11   12 , Jennifer H Jain  1 , Tracy Pondo  1 , Lesley McGee  1 , Bernard W Beall  1 , Stephanie J Schrag  1
Affiliations
Multicenter Study

Epidemiology of Invasive Early-Onset and Late-Onset Group B Streptococcal Disease in the United States, 2006 to 2015: Multistate Laboratory and Population-Based Surveillance

Srinivas Acharya Nanduri et al. JAMA Pediatr. .

Erratum in

  • Errors in Byline, Abstract, and Discussion.
    [No authors listed] [No authors listed] JAMA Pediatr. 2019 Mar 1;173(3):296. doi: 10.1001/jamapediatrics.2019.0061. JAMA Pediatr. 2019. PMID: 30830159 Free PMC article. No abstract available.
  • Error in Results.
    [No authors listed] [No authors listed] JAMA Pediatr. 2019 May 1;173(5):502. doi: 10.1001/jamapediatrics.2019.0953. JAMA Pediatr. 2019. PMID: 30985896 No abstract available.

Abstract

Importance: Invasive disease owing to group B Streptococcus (GBS) remains an important cause of illness and death among infants younger than 90 days in the United States, despite declines in early-onset disease (EOD; with onset at 0-6 days of life) that are attributed to intrapartum antibiotic prophylaxis (IAP). Maternal vaccines to prevent infant GBS disease are currently under development.

Objective: To describe incidence rates, case characteristics, antimicrobial resistance, and serotype distribution of EOD and late-onset disease (LOD; with onset at 7-89 days of life) in the United States from 2006 to 2015 to inform IAP guidelines and vaccine development.

Design, setting, and participants: This study used active population-based and laboratory-based surveillance for invasive GBS disease conducted through Active Bacterial Core surveillance in selected counties of 10 states across the United States. Residents of Active Bacterial Core surveillance areas who were younger than 90 days and had invasive GBS disease in 2006 to 2015 were included. Data were analyzed from December 2017 to April 2018.

Exposures: Group B Streptococcus isolated from a normally sterile site.

Main outcomes and measures: Early-onset disease and LOD incidence rates and associated GBS serotypes and antimicrobial resistance.

Results: The Active Bacterial Core surveillance program identified 1277 cases of EOD and 1387 cases of LOD. From 2006 to 2015, EOD incidence declined significantly from 0.37 to 0.23 per 1000 live births (P < .001), and LOD rates remained stable (mean, 0.31 per 1000 live births). Among the mothers of 1277 infants with EOD, 617 (48.3%) had no indications for IAP and did not receive it, and 278 (21.8%) failed to receive IAP despite having indications. Serotype data were available for 1743 of 1897 patients (91.3%) from 7 sites that collect GBS isolates. Among patients with EOD, serotypes Ia (242 [27.3%]) and III (242 [27.3%]) were most common. Among patients with LOD, serotype III was most common (481 [56.2%]), and this increased from 2006 to 2015 from 0.12 to 0.20 cases per 1000 live births (P < .001). Serotype IV caused 53 cases (6.2%) of EOD and LOD combined. The 6 most common serotypes (Ia, Ib, II, III, IV, and V) caused 881 EOD cases (99.3%) and 853 LOD cases (99.7%). No β-lactam resistance was identified; 359 isolates (20.8%) tested showed constitutive clindamycin resistance. In 2015, an estimated 840 EOD cases and 1265 LOD cases occurred nationally.

Conclusions and relevance: The rates of LOD among US infants are now higher than EOD rates. Combined with addressing IAP implementation gaps, an effective vaccine covering the most common serotypes might further reduce EOD rates and help prevent LOD, for which there is no current public health intervention.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Snippes Vagnone reports receiving grants from a Cooperative Agreement with the Centers for Disease Control and Prevention (CDC) during the conduct of the study. Dr Schaffner reports grants from the CDC during the conduct of the study and personal fees from Pfizer, Merck, SutroVax, Shionogi, Dynavax, and Seqirus outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Rates of Early-Onset and Late-Onset Invasive Group B Streptococcal Disease
Figure 2.
Figure 2.. Description of Missed Opportunities for Intrapartum Antibiotic Prophylaxis (IAP) Among Early-Onset Disease Cases, 2006 to 2015
GBS indicates group B streptococcal disease.
Figure 3.
Figure 3.. Incidence of Early-Onset and Late-Onset Group B Streptococcal Disease by Serotype, 2006 to 2015
Of the 10 Active Bacterial Core surveillance sites, only those in Colorado, Georgia, Maryland, Minnesota, New Mexico, New York, and Oregon collect isolates for characterization including serotyping and antimicrobial susceptibility testing.
Figure 4.
Figure 4.. Trends in Percentage of Macrolide Resistance Among Isolates Collected and Tested Through Active Bacterial Core Surveillance Sites, 2006 to 2015
Data on macrolide-inducible clindamycin resistance were available only from 2011 onward. Of the 10 Active Bacterial Core surveillance sites, only those in Colorado, Georgia, Maryland, Minnesota, New Mexico, New York, and Oregon collect isolates for characterization including serotyping and antimicrobial susceptibility testing.
See this image and copyright information in PMC

Comment in

References

    1. Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine. 2013;31(suppl 4):D20-D26. doi:10.1016/j.vaccine.2012.11.056 - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention . Prevention of perinatal group B streptococcal disease: a public health perspective. MMWR Recomm Rep. 1996;45(RR-7):1-24. - PubMed
    1. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep. 2002;51(RR-11):1-22. - PubMed
    1. Verani JR, McGee L, Schrag SJ; Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC) . Prevention of perinatal group B streptococcal disease—revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010;59(RR-10):1-36. - PubMed
    1. Phares CR, Lynfield R, Farley MM, et al. ; Active Bacterial Core surveillance/Emerging Infections Program Network . Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA. 2008;299(17):2056-2065. doi:10.1001/jama.299.17.2056 - DOI - PubMed

Publication types